Acute myelogenous leukemia and aging. Clinical interactions.
about
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk featuresA phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaMulti-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaCost of cancer clinical trials in elderly patients.Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Survival for older patients with acute myeloid leukemia: a population-based studyDevelopment of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideTipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.Tipifarnib in the treatment of acute myeloid leukemia.Identification of polymorphisms in cancer patients that differentially affect survival with age.Acute myeloid leukemia in elderly patients: experience of a single center.
P2860
Q34781553-2BA3E390-959A-4B0C-921A-8717B040D255Q35628954-E40ABA74-35D0-4ABE-8FE6-6BADD12F81A6Q35651754-95F6FDB6-5537-4DE0-9891-082FA47E89B0Q35688141-298259F8-B5E4-4BCA-8B44-07876BD79EFBQ35984641-575E65BA-C7A1-408D-8C8F-0D54771EAD14Q36429603-0BA6A20F-9F21-4DF5-8EB8-3C22E5476C46Q36662052-06B11495-561E-495D-818A-0A3420068019Q36946766-62712C72-8C9E-4C3F-890B-9263F6BA7D22Q37201853-7330A0AF-680E-44F3-82DF-C14BA58AF5C3Q37586897-2214897B-C579-44E6-9D2F-85DA05B8D718Q40170336-978626AE-E749-4F1B-8EE4-1FEE4BFDD301Q42217527-A86CDCF0-A339-4E27-A4A3-F5FBC5584726Q47114556-14DE724E-75F4-4151-89AB-A8BFC65E9034Q47853422-386CA7DD-58FC-4B6E-A5DF-F0FE246B4859
P2860
Acute myelogenous leukemia and aging. Clinical interactions.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Acute myelogenous leukemia and aging. Clinical interactions.
@ast
Acute myelogenous leukemia and aging. Clinical interactions.
@en
type
label
Acute myelogenous leukemia and aging. Clinical interactions.
@ast
Acute myelogenous leukemia and aging. Clinical interactions.
@en
prefLabel
Acute myelogenous leukemia and aging. Clinical interactions.
@ast
Acute myelogenous leukemia and aging. Clinical interactions.
@en
P2093
P1476
Acute myelogenous leukemia and aging. Clinical interactions.
@en
P2093
P304
P356
10.1016/S0889-8588(05)70287-2
P577
2000-02-01T00:00:00Z